Hydroxocobalamin, the form most commonly used in the UK, may cause: Injection site reactions (pain, redness, or swelling) Temporary reddish discolouration of urine Rarely, hypersensitivity reactions Very rarely, hypokalaemia in severely deficient patients when treatment is initiated (potassium levels should be monitored in severe deficiency) B12 injections are considered very safe, with no upper tolerable limit established, as excess B12 is excreted in urine
The global prevalence of AD is projected to increase from 57 million to 152 million by 2050, imposing a significant economic burden on society [1]
Once opened, use within 30 days
It has successfully completed Phase III clinical trials and has been approved by the U.S
TB-500 has a coherent animal story built on stem-cell activation, but essentially no human hair-growth data at all, making it the more speculative of the two for this use